Delcath Gets FDA Clearance for Phase 2 Liver Cancer Trial

MT Newswires Live12-02

Delcath Systems (DCTH) said Monday that the US Food and Drug Administration cleared its investigational new drug application for a phase 2 clinical trial of Hapzato, in combination with standard of care, in liver-dominant metastatic colorectal cancer.

The trial will evaluate the safety and efficacy of the combination therapy, with a primary endpoint of hepatic progression-free survival that is expected to be read out by the end of 2027, according to the company.

Delcath Systems said it expects to enroll about 90 patients for the study and plans to start enrollment in the second half of 2025.

Price: 11.76, Change: -0.13, Percent Change: -1.05

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2488706126?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-02 23:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488706126","market":"fut","top_or_hot":-1,"title":"Delcath Gets FDA Clearance for Phase 2 Liver Cancer Trial","media":"MT Newswires Live","content":"<html><body><p> Delcath Systems (DCTH) said Monday that the US Food and Drug Administration cleared its investigational new drug application for a phase 2 clinical trial of Hapzato, in combination with standard of care, in liver-dominant metastatic colorectal cancer.</p><p>The trial will evaluate the safety and efficacy of the combination therapy, with a primary endpoint of hepatic progression-free survival that is expected to be read out by the end of 2027, according to the company.</p><p>Delcath Systems said it expects to enroll about 90 patients for the study and plans to start enrollment in the second half of 2025.</p><p>Price: 11.76, Change: -0.13, Percent Change: -1.05</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Delcath Gets FDA Clearance for Phase 2 Liver Cancer Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDelcath Gets FDA Clearance for Phase 2 Liver Cancer Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-02 23:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Delcath Systems (DCTH) said Monday that the US Food and Drug Administration cleared its investigational new drug application for a phase 2 clinical trial of Hapzato, in combination with standard of ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DCTH","symbol_name":"迪卡斯","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2488706126","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488706126","pubTimestamp":1733152643,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Delcath Systems  said Monday that the US Food and Drug Administration cleared its investigational new drug application for a phase 2 clinical trial of Hapzato, in combination with standard of care, in liver-dominant metastatic colorectal cancer.The trial will evaluate the safety and efficacy of the combination therapy, with a primary endpoint of hepatic progression-free survival that is expected to be read out by the end of 2027, according to the company.Delcath Systems said it expects to enroll about 90 patients for the study and plans to start enrollment in the second half of 2025.Price: 11.76, Change: -0.13, Percent Change: -1.05","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DCTH":"迪卡斯","BK4082":"医疗保健设备"},"translate_title":"Delcath获得FDA批准进行2期肝癌试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCTH":0.9},"content_text":"Delcath Systems (DCTH) said Monday that the US Food and Drug Administration cleared its investigational new drug application for a phase 2 clinical trial of Hapzato, in combination with standard of care, in liver-dominant metastatic colorectal cancer.The trial will evaluate the safety and efficacy of the combination therapy, with a primary endpoint of hepatic progression-free survival that is expected to be read out by the end of 2027, according to the company.Delcath Systems said it expects to enroll about 90 patients for the study and plans to start enrollment in the second half of 2025.Price: 11.76, Change: -0.13, Percent Change: -1.05","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2488706126"}